The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Angela Huttner(University Hospital of Geneva), Claire‐Anne Siegrist(University of Geneva), Axel Finckh(University Hospital of Geneva), Patricia Fast(International AIDS Vaccine Initiative), Christophe Combescure, Barbara Lemaître, Sabine Yerly(Unknown), Ana Rita Gonçalves(University Hospital of Geneva), Gürkan Kaya(University Hospital of Geneva), Julie-Anne Dayer(Flinders University), Markus Eickmann(Goethe University Frankfurt), Marie Paule Kiény(Medicines Patent Pool), Alain Matthey, Laurent Kaiser(University Hospital of Geneva), Jules Desmeules(University Hospital of Geneva), Vasee Moorthy(World Health Organization), Stephan Becker(Philipps University of Marburg), Jay W. Hooper(United States Army Medical Research Institute of Infectious Diseases), Steve Kwilas(United States Army Medical Research Institute of Infectious Diseases), Floriane Auderset, Peter Silvera(United States Army Medical Research Institute of Infectious Diseases), Verena Krähling(Philipps University of Marburg)
Cited by 278
Related Papers
Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome
|New England Journal of Medicine|2003|4.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma
|Nature Genetics|2016|495